158 related articles for article (PubMed ID: 14752821)
1. Viral features of lamivudine resistant hepatitis B genotypes A and D.
Zöllner B; Petersen J; Puchhammer-Stöckl E; Kletzmayr J; Sterneck M; Fischer L; Schröter M; Laufs R; Feucht HH
Hepatology; 2004 Jan; 39(1):42-50. PubMed ID: 14752821
[TBL] [Abstract][Full Text] [Related]
2. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
3. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
Kazim SN; Chauhan R; Das BC; Sarin SK
J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
[TBL] [Abstract][Full Text] [Related]
4. Genetic heterogeneity of the precore and the core promoter region of genotype C hepatitis B virus during lamivudine therapy.
Kuwahara R; Kumashiro R; Murashima S; Ogata K; Tanaka K; Hisamochi A; Hino T; Ide T; Tanaka E; Koga Y; Sata M
J Med Virol; 2004 Jan; 72(1):26-34. PubMed ID: 14635007
[TBL] [Abstract][Full Text] [Related]
5. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.
Lok AS; Hussain M; Cursano C; Margotti M; Gramenzi A; Grazi GL; Jovine E; Benardi M; Andreone P
Hepatology; 2000 Nov; 32(5):1145-53. PubMed ID: 11050068
[TBL] [Abstract][Full Text] [Related]
6. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation.
Ben-Ari Z; Daudi N; Klein A; Sulkes J; Papo O; Mor E; Samra Z; Gadba R; Shouval D; Tur-Kaspa R
Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951
[TBL] [Abstract][Full Text] [Related]
7. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy.
Ciancio A; Smedile A; Rizzetto M; Lagget M; Gerin J; Korba B
Hepatology; 2004 Jan; 39(1):64-73. PubMed ID: 14752824
[TBL] [Abstract][Full Text] [Related]
8. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
[TBL] [Abstract][Full Text] [Related]
9. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
[TBL] [Abstract][Full Text] [Related]
10. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
12. Precore stop codon mutation of hepatitis B virus is associated with low breakthrough rate following long-term lamivudine therapy.
Shin JW; Chung YH; Choi MH; Kim JA; Ryu SH; Jang MK; Kim IS; Park NH; Lee HC; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):844-9. PubMed ID: 15946130
[TBL] [Abstract][Full Text] [Related]
13. Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C.
Kobayashi M; Suzuki F; Akuta N; Suzuki Y; Arase Y; Ikeda K; Hosaka T; Sezaki H; Kobayashi M; Iwasaki S; Sato J; Watahiki S; Miyakawa Y; Kumada H
J Med Virol; 2006 Oct; 78(10):1276-83. PubMed ID: 16927289
[TBL] [Abstract][Full Text] [Related]
14. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy.
Cho SW; Hahm KB; Kim JH
Hepatology; 2000 Nov; 32(5):1163-9. PubMed ID: 11050070
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations.
Watanabe K; Takahashi T; Takahashi S; Okoshi S; Ichida T; Aoyagi Y
J Gastroenterol Hepatol; 2005 Mar; 20(3):441-9. PubMed ID: 15740490
[TBL] [Abstract][Full Text] [Related]
16. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
17. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C.
Hsieh TH; Tseng TC; Liu CJ; Lai MY; Chen PJ; Hsieh HL; Chen DS; Kao JH
Antivir Ther; 2009; 14(8):1157-63. PubMed ID: 20032545
[TBL] [Abstract][Full Text] [Related]
19. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy.
Chen CH; Lee CM; Lu SN; Changchien CS; Wang JC; Wang JH; Hung CH; Hu TH
J Hepatol; 2006 Jan; 44(1):76-82. PubMed ID: 16298013
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
